Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine Orodispersible vs Oral Preference in Schizophrenia
NCT00324051Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2006
- Primary completion
- Sep 2007
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 4, randomised, open-label trial of olanzapine in schizophrenia (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Patient preference measured by a simple preference question at 12 weeks. Started May 2006; status: completed.
02
Drugs
olanzapine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00324051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00324051.